ITMI20121965A1 - TOPIC COMPOSITION FOR TRANSEPIDERMIC OR TRANSDERMIC RELEASE OF PARACETAMOL - Google Patents
TOPIC COMPOSITION FOR TRANSEPIDERMIC OR TRANSDERMIC RELEASE OF PARACETAMOL Download PDFInfo
- Publication number
- ITMI20121965A1 ITMI20121965A1 IT001965A ITMI20121965A ITMI20121965A1 IT MI20121965 A1 ITMI20121965 A1 IT MI20121965A1 IT 001965 A IT001965 A IT 001965A IT MI20121965 A ITMI20121965 A IT MI20121965A IT MI20121965 A1 ITMI20121965 A1 IT MI20121965A1
- Authority
- IT
- Italy
- Prior art keywords
- agent
- composition
- paracetamol
- weight
- pharmaceutical
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 89
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims description 47
- 229960005489 paracetamol Drugs 0.000 title claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 238000009472 formulation Methods 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 17
- 239000002537 cosmetic Substances 0.000 claims description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 8
- 206010040954 Skin wrinkling Diseases 0.000 claims description 7
- 230000037303 wrinkles Effects 0.000 claims description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical group OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 229940101267 panthenol Drugs 0.000 claims description 6
- 235000020957 pantothenol Nutrition 0.000 claims description 6
- 239000011619 pantothenol Substances 0.000 claims description 6
- 239000008177 pharmaceutical agent Substances 0.000 claims description 6
- 206010040882 skin lesion Diseases 0.000 claims description 6
- 231100000444 skin lesion Toxicity 0.000 claims description 6
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 5
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 5
- 208000000558 Varicose Ulcer Diseases 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000004006 olive oil Substances 0.000 claims description 5
- 235000008390 olive oil Nutrition 0.000 claims description 5
- BSXFOBDOGHFWOC-KRCBVYEFSA-N (2S)-1-[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide Chemical compound C([C@H](NC(=O)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 BSXFOBDOGHFWOC-KRCBVYEFSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000004927 clay Substances 0.000 claims description 4
- 229940105990 diglycerin Drugs 0.000 claims description 4
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 4
- 238000005868 electrolysis reaction Methods 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 3
- 244000215068 Acacia senegal Species 0.000 claims description 3
- 244000303965 Cyamopsis psoralioides Species 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims description 3
- 229920000084 Gum arabic Polymers 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 3
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 claims description 3
- 229920001615 Tragacanth Polymers 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000000205 acacia gum Substances 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 239000003974 emollient agent Substances 0.000 claims description 3
- 235000020721 horse chestnut extract Nutrition 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- -1 hydroxypropyl Chemical group 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 229960001860 salicylate Drugs 0.000 claims description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 229950009883 tocopheryl nicotinate Drugs 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004990 Smectic liquid crystal Substances 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- UGZICOVULPINFH-UHFFFAOYSA-N acetic acid;butanoic acid Chemical compound CC(O)=O.CCCC(O)=O UGZICOVULPINFH-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 229940064062 alpha-glucan oligosaccharide Drugs 0.000 claims description 2
- 229940067596 butylparaben Drugs 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 claims description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 235000011083 sodium citrates Nutrition 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 206010011985 Decubitus ulcer Diseases 0.000 claims 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 241000416162 Astragalus gummifer Species 0.000 claims 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 239000000440 bentonite Substances 0.000 claims 1
- 229910000278 bentonite Inorganic materials 0.000 claims 1
- 229940092782 bentonite Drugs 0.000 claims 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 229920006218 cellulose propionate Polymers 0.000 claims 1
- 239000012154 double-distilled water Substances 0.000 claims 1
- 229940070721 polyacrylate Drugs 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 235000010487 tragacanth Nutrition 0.000 claims 1
- 239000000196 tragacanth Substances 0.000 claims 1
- 229940116362 tragacanth Drugs 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 description 9
- 239000001692 EU approved anti-caking agent Substances 0.000 description 7
- 239000000945 filler Substances 0.000 description 7
- 239000002304 perfume Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Polymers [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000035874 Excoriation Diseases 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 229940124532 absorption promoter Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229920000310 Alpha glucan Polymers 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
“Composizione topica per il rilascio transepidermico o transdermico di paracetamolo" "Topical composition for the transepidermal or transdermal release of paracetamol"
CAMPO DELL'INVENZIONE FIELD OF THE INVENTION
La presente invenzione si riferisce ad una composizione topica transepidermica o transdermica comprendente paracetamolo, eccipienti farmaceuticamente o cosmeticamente accettabili ed un agente veicolante transepidermico o transdermico consistente in acqua elettrolizzata acida ed un agente reologico. L’invenzione riguarda altresì formulazioni cosmetiche e farmaceutiche comprendenti detta composizione topica transepidermica o transdermica ed il loro uso come coadiuvanti nel trattamento di lesioni cutanee, dermatite atopica, rughe, liposclerosi, piaghe da decubito, ulcere varicose e diabetiche. The present invention relates to a transepidermal or transdermal topical composition comprising paracetamol, pharmaceutically or cosmetically acceptable excipients and a transepidermal or transdermal carrier agent consisting of acid electrolyzed water and a rheological agent. The invention also relates to cosmetic and pharmaceutical formulations comprising said transepidermal or transdermal topical composition and their use as adjuvants in the treatment of skin lesions, atopic dermatitis, wrinkles, liposclerosis, bedsores, varicose and diabetic ulcers.
STATO DELLA TECNICA STATE OF THE TECHNIQUE
Il paracetamolo (o acetaminofene) (N-acetil-para-amminofenolo) à ̈ una molecola molto piccola a carattere lipofilo ed à ̈ noto per l’azione analgesica ed antipiretica, ad esempio nei comuni preparati da banco per le forme virali da raffreddamento, o nei farmaci destinati al trattamento del dolore acuto e cronico. Paracetamol (or acetaminophen) (N-acetyl-para-aminophenol) is a very small molecule with a lipophilic character and is known for its analgesic and antipyretic action, for example in common over-the-counter preparations for cooling viral forms. , or in drugs intended for the treatment of acute and chronic pain.
È generalmente somministrato da solo o in combinazione con altri ingredienti terapeuticamente attivi in dosaggi unitari di 500 mg o 1 g per via orale. Tuttavia, tale somministrazione non à ̈ soddisfacente. Infatti, quando le molecole di paracetamolo sono introdotte nell'esofago e nello stomaco, esse sono soggette all’effetto detto “di primo passaggio digestivo†, ossia alterazioni e dispersioni legate all'ambiente dello stomaco o a cambiamenti fisiologici intestinali. Esse vengono poi sottoposte al cosiddetto “primo passaggio epatico" che provoca il loro metabolismo e/o la loro degradazione più o meno intensa, con formazione di numerosi metaboliti, prevalentemente inattivi o tossici, senza contare che il paracetamolo à ̈ tossico per il fegato quando viene somministrato ad un dosaggio superiore a 4 g. It is generally administered alone or in combination with other therapeutically active ingredients in unit dosages of 500 mg or 1 g orally. However, such administration is not satisfactory. In fact, when the paracetamol molecules are introduced into the esophagus and stomach, they are subject to the so-called â € œof first digestive passâ € effect, ie alterations and dispersions linked to the stomach environment or to intestinal physiological changes. They are then subjected to the so-called â € œhepatic first passage "which causes their metabolism and / or their more or less intense degradation, with the formation of numerous metabolites, mainly inactive or toxic, not to mention that paracetamol is toxic for the liver. when administered at a dosage greater than 4 g.
Dunque, la dose di ingrediente attivo veramente biodisponibile à ̈ bassa, pari in media tra 60 e 75% della dose somministrata, senza considerare le molteplici variabili inter- ed intra-individui. Inoltre, l'emivita del paracetamolo à ̈ relativamente breve, ossia tra 1 e 3 ore. Therefore, the dose of truly bioavailable active ingredient is low, on average between 60 and 75% of the administered dose, without considering the multiple inter- and intra-individual variables. Furthermore, the half-life of paracetamol is relatively short, i.e. between 1 and 3 hours.
Poiché si lega molto poco alle proteine piasmatiche a causa della sua natura lipofila, la molecola di paracetamolo si distribuisce velocemente nella maggior parte dei compartimenti de ’organismo. Così, una porzione significativa della dose somministrata viene diluita nel sistema vascolare dell'organismo ed allo stesso tempo negli spazi extravascolari, organici e soprattutto tissutali, così riducendo la percentuale di paracetamolo effettivamente disponibile che può accedere i recettori cerebrali centrali per esercitarvi la sua attività terapeutica, di breve durata di azione. Because it binds very little to piasmatic proteins due to its lipophilic nature, the paracetamol molecule is rapidly distributed in most compartments of the organism. Thus, a significant portion of the administered dose is diluted in the vascular system of the organism and at the same time in the extravascular, organic and above all tissue spaces, thus reducing the percentage of paracetamol actually available that can access the central brain receptors to exercise its therapeutic activity, of short duration of action.
Inoltre, l’avvio dell’efficacia terapeutica per il paziente richiede tra 30 e 60 minuti dopo la somministrazione, corrispondente al periodo di assorbimento digestivo, di metabolizzazione e di diffusione vascolare e poi tissutale. Furthermore, the start of therapeutic efficacy for the patient takes between 30 and 60 minutes after administration, corresponding to the period of digestive absorption, metabolization and vascular and then tissue diffusion.
Pertanto, si rilevano due problemi principali. Il primo problema à ̈ che si rende necessario somministrare una dose adeguata al paziente tenendo conto della diluizione e della dispersione nell’organismo, in modo che la parte significativamente attiva che raggiunge gli effettori centrali sia efficace. Infatti, un rilevante problema associato alla somministrazione di farmaci per via orale, à ̈ che il livello di concentrazione che deve essere raggiunto nel sangue deve essere significativo al fine di trattare efficacemente le aree distali di dolore o infiammazione. Questi livelli sono spesso molto più elevati di quanto sarebbe necessario se fosse possibile per indirizzare con precisione il particolare sito da trattare. Therefore, there are two main problems. The first problem is that it is necessary to administer an adequate dose to the patient taking into account the dilution and dispersion in the organism, so that the significantly active part that reaches the central effectors is effective. Indeed, a major problem associated with oral drug administration is that the level of concentration that must be achieved in the blood must be significant in order to effectively treat distal areas of pain or inflammation. These levels are often much higher than would be necessary if it were possible to precisely target the particular site to be treated.
Il secondo à ̈ il tempo di latenza dovuto al metabolismo ed alla distribuzione nell’organismo prima che la molecola agisca ed il paziente ne tragga beneficio. Da ciò derivano effetti collaterali associati all’uso di paracetamolo, in particolare epatotossicità e, in rari casi, nefrotossicità nell'uomo e in animali da esperimento. Un sovradosaggio di paracetamolo genera necrosi epatica dose-dipendente e potenzialmente fatale, come pure, in rari casi, necrosi tubulare renale e ipoglicemia. The second is the latency time due to metabolism and distribution in the organism before the molecule acts and the patient benefits from it. From this derive side effects associated with the use of paracetamol, in particular hepatotoxicity and, in rare cases, nephrotoxicity in humans and in experimental animals. An overdose of paracetamol results in dose-dependent and life-threatening hepatic necrosis, as well as, in rare cases, renal tubular necrosis and hypoglycemia.
Si riscontra quindi la necessità di somministrare una quantità immediatamente biodisponibile di paracetamolo, che consenta al paracetamolo di espletare la sua funzione rapidamente ed efficacemente, possibilmente in situ, in modo da evitare il rischio di sovradosaggio per raggiungere la quantità necessaria. There is therefore the need to administer an immediately bioavailable quantity of paracetamol, which allows the paracetamol to perform its function quickly and effectively, possibly in situ, in order to avoid the risk of overdose to reach the necessary quantity.
Scopo della presente invenzione à ̈ dunque quello di trovare un prodotto efficace per le finalità sopra indicate, ma che al tempo stesso sia altamente biocompatibile e tollerabile. The aim of the present invention is therefore to find an effective product for the purposes indicated above, but which at the same time is highly biocompatible and tolerable.
SOMMARIO DELL’INVENZIONE SUMMARY OF THE INVENTION
Lo scopo indicato più sopra à ̈ stato raggiunto mediante una composizione topica transepidermica o transdermica comprendente paracetamolo, eccipienti farmaceuticamente o cosmeticamente accettabili ed un agente veicolante transepidermico o transdermico consistente in acqua elettrolizzata acida avente pH da 1,0 a 4,0 e comprendente cluster di acqua, aventi da 5 a 10 molecole di acqua per cluster, ed un agente reologico. The aim indicated above has been achieved by means of a transepidermal or transdermal topical composition comprising paracetamol, pharmaceutically or cosmetically acceptable excipients and a transepidermal or transdermal carrier agent consisting of acid electrolyzed water having a pH from 1.0 to 4.0 and comprising clusters of water, having 5 to 10 water molecules per cluster, and a rheological agent.
Sotto un altro aspetto, la presente invenzione concerne una formulazione farmaceutica o cosmetica comprendente la composizione topica transepidermica o transdermica ed almeno un agente farmaceutico o cosmetico scelto tra agente umettante, agente lenitivo, agente emolliente, agente conservante, agente chelante, agente addensante, agente antiossidante e loro miscela. Under another aspect, the present invention relates to a pharmaceutical or cosmetic formulation comprising the transepidermal or transdermal topical composition and at least one pharmaceutical or cosmetic agent selected from wetting agent, soothing agent, emollient agent, preservative agent, chelating agent, thickening agent, antioxidant agent. and their mixture.
Sotto un ulteriore aspetto, la presente invenzione concerne l’uso della formulazione farmaceutica o cosmetica come coadiuvante nel trattamento di lesioni cutanee, artrite, dermatite atopica, rughe, liposclerosi, piaghe da decubito, ulcere varicose e diabetiche. From a further aspect, the present invention relates to the use of the pharmaceutical or cosmetic formulation as an adjuvant in the treatment of skin lesions, arthritis, atopic dermatitis, wrinkles, liposclerosis, bedsores, varicose and diabetic ulcers.
DESCRIZIONE DELLA FIGURA DESCRIPTION OF THE FIGURE
Le caratteristiche ed i vantaggi della presente invenzione saranno evidenti dalla descrizione dettagliata di seguito riportata, e dagli esempi realizzativi forniti a titolo illustrativo e non limitativo, nonché dalla Figura 1 in cui à ̈ mostrato lo spettro NMR dei campioni dell’Esempio 13. The characteristics and advantages of the present invention will be evident from the detailed description given below, and from the embodiment examples provided for illustrative and non-limiting purposes, as well as from Figure 1 in which the NMR spectrum of the samples of Example 13 is shown.
DESCRIZIONE DETTAGLIATA DELL’INVENZIONE DETAILED DESCRIPTION OF THE INVENTION
L’invenzione ha quindi come oggetto una composizione topica transepidermica o transdermica comprendente paracetamolo, eccipienti farmaceuticamente o cosmeticamente accettabili ed un agente veicolante transepidermico o transdermico consistente in acqua elettrolizzata acida avente pH da 1,0 a 4,0 e comprendente cluster di acqua, aventi da 5 a 10 molecole di acqua per cluster, ed un agente reologico. The invention therefore relates to a transepidermal or transdermal topical composition comprising paracetamol, pharmaceutically or cosmetically acceptable excipients and a transepidermal or transdermal carrier agent consisting of acid electrolyzed water having a pH from 1.0 to 4.0 and comprising clusters of water, having from 5 to 10 water molecules per cluster, and a rheological agent.
Si à ̈ infatti sorprendentemente trovato che tale composizione à ̈ particolarmente efficace nella somministrazione transepidermica o transdermica del paracetamolo, come sarà dimostrato negli Esempi forniti di seguito. Indeed, it has been surprisingly found that this composition is particularly effective in the transepidermal or transdermal administration of paracetamol, as will be demonstrated in the Examples provided below.
Nella composizione dell'invenzione, il paracetamolo può essere in quantità da 0,005 a 15% in peso, sul peso della composizione. In the composition of the invention, paracetamol can be in an amount from 0.005 to 15% by weight, based on the weight of the composition.
Preferibilmente, nella composizione dell’invenzione, il paracetamolo à ̈ in quantità da 0,01 a 5% in peso, sul peso della composizione. Preferably, in the composition of the invention, paracetamol is in an amount from 0.01 to 5% by weight, based on the weight of the composition.
Più preferibilmente, nella composizione dell’invenzione, il paracetamolo à ̈ in quantità da 0,05 a 2% in peso, sul peso della composizione. More preferably, in the composition of the invention, paracetamol is in an amount from 0.05 to 2% by weight, based on the weight of the composition.
Nella composizione dell’invenzione, detto agente Teologico può essere naturale oppure sintetico, oppure una loro miscela. Preferibilmente detto agente reologico à ̈ argilla smettica, argilla Hormite, gomma xantana, carbossimetilcellulosa di sodio, metilcellulosa, idrossipropilmetilcellulosa, idrossietilcellulosa, idrossipropilcellulosa, carragenina, idrossipropil guar, gomma arabica, gomma tragacanth, sodio alginato, poliacrilato, carbomer, bentonite, esteri di cellulosa, preferibilmente C1-C4 esteri di cellulosa, ancor più preferibilmente acetato di cellulosa, acetato propionato di cellulosa, acetato butirrato di cellulosa, esteri di carbossimetilcellulosa, preferibilmente C1-C4 esteri di carbossimetilcellulosa, ancor più preferibilmente carbossimetil cellulosa acetato butirrato, o loro miscela. Secondo una forma di realizzazione preferita, l’agente reologico à ̈ scelto dal gruppo consistente in gomma xantana, carbossimetilcellulosa di sodio, metilcellulosa, idrossipropilmetilcellulosa, idrossietilcellulosa, idrossipropilcellulosa, carragenina, idrossipropil guar, gomma arabica, gomma tragacanth, sodio alginato, poliacrilato, e loro miscele. In the composition of the invention, said theological agent can be natural or synthetic, or a mixture thereof. Preferably said rheological agent is smectic clay, Hormite clay, xanthan gum, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carrageenan, hydroxypropyl guar, gum arabic, tragacanth gum, sodium alginate, polyacrylate esters, polyacrylate , preferably C1-C4 cellulose esters, even more preferably cellulose acetate, cellulose acetate propionate, cellulose acetate butyrate, carboxymethylcellulose esters, preferably C1-C4 esters of carboxymethylcellulose, even more preferably carboxymethyl cellulose acetate butyrate, or a mixture thereof. According to a preferred embodiment, the rheological agent is selected from the group consisting of xanthan gum, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carrageenan, hydroxypropyl guar, gum arabic, tragacanth gum, sodium alginate, polyacrylate and their mixtures.
Preferibilmente, detto agente reologico à ̈ in quantità da 0,0001 a 5% in peso, sul peso dell’agente veicolante transepidermico o transdermico. Preferably, said rheological agent is in an amount from 0.0001 to 5% by weight, based on the weight of the transepidermal or transdermal carrier agent.
Più preferibilmente, detto agente reologico à ̈ in quantità da 0,001 a 2% in peso, sul peso dell’agente veicolante transepidermico o transdermico. More preferably, said rheological agent is in an amount from 0.001 to 2% by weight, based on the weight of the transepidermal or transdermal carrier agent.
L'agente veicolante transepidermico o transdermico della composizione dell’invenzione comprende inoltre acqua elettrolizzata acida avente pH da 1,0 a 4,0 e comprendente cluster di acqua aventi da 5 a 10 molecole di acqua per cluster. The transepidermal or transdermal carrier agent of the composition of the invention further comprises acid electrolyzed water having pH from 1.0 to 4.0 and comprising water clusters having from 5 to 10 water molecules per cluster.
Per gli scopi della presente invenzione, detta “acqua elettrolizzata acida" à ̈ acqua ottenibile da un procedimento in cui una soluzione di acqua distillata ed un elettrolita, preferibilmente un sale inorganico, à ̈ sottoposta ad elettrolisi mediante applicazione di una differenza di potenziale di 10-100 Volts. Nell’intorno del catodo della cella elettrolitica si concentra quindi acqua alcalina, mentre nell'intorno dell’anodo si concentra acqua acida. Inoltre, per effetto dell’elettrolisi, i cluster di molecole d’acqua naturalmente presenti in aggregati anche di 15-20 molecole di acqua ciascuno, si riducono in dimensioni a 5-10 molecole di acqua ciascuno, preferibilmente a 5-6 molecole di acqua ciascuno. Ciò risulta estremamente vantaggioso in quanto cluster di queste dimensioni superano agevolmente la barriera epidermica, arrivando sorprendentemente a trasportare il paracetamolo, che tal quale non à ̈ somministrabile transdermicamente. Infatti, il paracetamolo à ̈ tipicamente somministrato per via orale, rettale, o iniettiva, generando gli svantaggi sopra discussi. For the purposes of the present invention, said â € œacid electrolyzed water "is water obtainable from a process in which a solution of distilled water and an electrolyte, preferably an inorganic salt, is subjected to electrolysis by applying a potential difference of 10-100 Volts. Alkaline water concentrates around the cathode of the electrolytic cell, while acid water concentrates around the anode. Furthermore, due to electrolysis, the clusters of water molecules naturally present in aggregates of even 15-20 water molecules each, they are reduced in size to 5-10 water molecules each, preferably to 5-6 water molecules each. This is extremely advantageous as clusters of these dimensions easily exceed the epidermal barrier, surprisingly arriving to transport paracetamol, which as it is cannot be administered transdermally. In fact, paracetamol is typically administered orally, rectally, or injected, generating the disadvantages discussed above.
Al termine del procedimento di elettrolisi, si separa la soluzione acquosa nella frazione acida e nella frazione basica, ottenendo “acqua elettrolizzata acida†ed “acqua elettrolizzata basica†rispettivamente. L'acqua elettrolizzata acida così ottenuta presenta un pH da 1,0 a 4,0, preferibilmente da 2,0 a 3,0. At the end of the electrolysis process, the aqueous solution is separated into the acid fraction and the basic fraction, obtaining â € œacid electrolyzed waterâ € and â € œelectrolyzed basic waterâ € respectively. The acid electrolyzed water thus obtained has a pH of 1.0 to 4.0, preferably 2.0 to 3.0.
Secondo una forma di realizzazione preferita, il pH dell’acqua elettrolizzata acida à ̈ 2,2. According to a preferred embodiment, the pH of the acid electrolyzed water is 2.2.
Eccipienti farmaceuticamente o cosmeticamente accettabili adatti alla composizione dell’invenzione possono essere scelti tra plasticizzanti, disaggreganti, glidanti, coloranti, leganti, lubrificanti, stabilizzanti, adsorbenti, conservanti, ritardanti di rilascio o loro miscele. Pharmaceutically or cosmetically acceptable excipients suitable for the composition of the invention can be selected from plasticizers, disaggregators, glidants, dyes, binders, lubricants, stabilizers, adsorbents, preservatives, release retardants or mixtures thereof.
È dunque da intendersi che la composizione della presente invenzione vantaggiosamente non comprende promotori di assorbimento, i quali sono responsabili di indesiderabili irritazioni cutanee. In tal senso, preferibilmente, la composizione topica transepidermica o transdermica dell’invenzione consiste essenzialmente in paracetamolo, eccipienti farmaceuticamente o cosmeticamente accettabili ed un agente veicolante transepidermico o transdermico consistente in acqua elettrolizzata acida avente pH da 1,0 a 4,0 e comprendente cluster di acqua, aventi da 5 a 10 molecole di acqua per cluster, ed un agente reologico, dal momento che tale combinazione di componenti consente un adeguato rilascio di paracetamolo per via transepidermica o transdermica grazie alla sola presenza dell’agente veicolante transepidermico o transdermico sopra descritto, quindi vantaggiosamente senza ricorrere all’uso di promotori di assorbimento. It is therefore to be understood that the composition of the present invention advantageously does not comprise absorption promoters, which are responsible for undesirable skin irritations. In this sense, preferably, the transepidermal or transdermal topical composition of the invention essentially consists of paracetamol, pharmaceutically or cosmetically acceptable excipients and a transepidermal or transdermal carrier agent consisting of acid electrolyzed water having a pH from 1.0 to 4.0 and comprising water cluster, having from 5 to 10 water molecules per cluster, and a rheological agent, since this combination of components allows for an adequate release of paracetamol via the transepidermal or transdermal route thanks to the sole presence of the transepidermal or transdermal carrier agent described above, therefore advantageously without resorting to the use of absorption promoters.
Secondo una forma di realizzazione preferita, la composizione dell’invenzione consiste in paracetamolo, eccipienti farmaceuticamente o cosmeticamente accettabili ed un agente veicolante transepidermico o transdermico consistente in acqua elettrolizzata acida avente pH da 1,0 a 4,0 e comprendente cluster di acqua, aventi da 5 a 10 molecole di acqua per cluster, ed un agente reologico. Sotto un altro aspetto, la composizione dell’invenzione à ̈ impiegata per l’uso esterno sia cosmetico che farmaceutico, in particolare come agente idratante cutaneo e come agente per la somministrazione transepidermica o transdermica di paracetamolo. According to a preferred embodiment, the composition of the invention consists of paracetamol, pharmaceutically or cosmetically acceptable excipients and a transepidermal or transdermal carrier agent consisting of acid electrolyzed water having a pH from 1.0 to 4.0 and comprising clusters of water, having from 5 to 10 water molecules per cluster, and a rheological agent. From another aspect, the composition of the invention is used for both cosmetic and pharmaceutical external use, in particular as a skin moisturizing agent and as an agent for the transepidermal or transdermal administration of paracetamol.
Sotto un altro aspetto, la presente invenzione concerne una formulazione farmaceutica o cosmetica comprendente la composizione topica transepidermica o transdermica sopra descritta, ed almeno un agente farmaceutico o cosmetico scelto tra agente umettante, agente lenitivo, agente emolliente, agente conservante, agente chelante, agente addensante, agente antiossidante e loro miscela. Under another aspect, the present invention relates to a pharmaceutical or cosmetic formulation comprising the transepidermal or transdermal topical composition described above, and at least one pharmaceutical or cosmetic agent selected from wetting agent, soothing agent, emollient agent, preservative agent, chelating agent, thickening agent , antioxidant agent and their mixture.
Preferibilmente, detto agente farmaceutico o cosmetico à ̈ pantenolo, glicerina, mannitolo, sodio citrato, acetil tetrapeptide-15, imidazolidinil urea, fenossietanolo, metil-parabene, etil-parabene, propil-parabene, butil-parabene, EDTA, disodio EDTA, diglicerina, olio di oliva, salicilato de silanodiol, oligosaccaride alfa-glucano, vitamina E, vitamina A, ascorbil palmitato, acido lipoico, estratto di ippocastano, estratto di Gingko Biloba, o nicotinato di tocoferile. Preferably, said pharmaceutical or cosmetic agent is panthenol, glycerin, mannitol, sodium citrate, acetyl tetrapeptide-15, imidazolidinyl urea, phenoxyethanol, methyl-paraben, ethyl-paraben, propyl-paraben, butyl-paraben, EDTA, disodium EDTA, diglycerin , olive oil, silanodiol salicylate, alpha-glucan oligosaccharide, vitamin E, vitamin A, ascorbyl palmitate, lipoic acid, horse chestnut extract, Gingko Biloba extract, or tocopheryl nicotinate.
Secondo una forma di realizzazione preferita, la formulazione farmaceutica o cosmetica dell’invenzione ulteriormente comprende acido ialuronico. According to a preferred embodiment, the pharmaceutical or cosmetic formulation of the invention further comprises hyaluronic acid.
Preferibilmente, la formulazione dell’invenzione à ̈ per uso esterno ed à ̈ in forma di crema, olio, emulsione, latte, spray, lozione, maschera protettiva, fondotinta, stick per labbra, lipogel o gel. Preferably, the formulation of the invention is for external use and is in the form of cream, oil, emulsion, milk, spray, lotion, protective mask, foundation, lip stick, lipogel or gel.
Sotto un ulteriore aspetto, la presente invenzione concerne l’uso della formulazione farmaceutica o cosmetica sopra descritta, come coadiuvante nel trattamento di lesioni cutanee, artrite, dermatite atopica, rughe, liposclerosi, piaghe da decubito, ulcere varicose e diabetiche. From a further aspect, the present invention relates to the use of the pharmaceutical or cosmetic formulation described above, as an adjuvant in the treatment of skin lesions, arthritis, atopic dermatitis, wrinkles, liposclerosis, bedsores, varicose and diabetic ulcers.
Per gli scopi della presente invenzione, con “lesioni cutanee†si intendono macchie, papule, vesciche, bolle, pustole, cisti, erosioni, abrasioni, arrossamenti, ulcere, screpolature, piaghe, telangectasia, desquamazioni, eritemi, ustioni, croste, lichenificazioni, escoriazioni, indurimenti, tagli, lacerazioni, o atrofie. For the purposes of the present invention, with `` skin lesions '' we mean spots, papules, blisters, bubbles, pustules, cysts, erosions, abrasions, redness, ulcers, cracks, sores, telangiectasia, desquamation, erythema, burns, scabs, lichenifications , abrasions, hardening, cuts, lacerations, or atrophies.
Infatti, come si vedrà dagli Esempi che seguono, tale formulazione applicata per via topica, à ̈ risultata presentare una buona efficacia nel promuovere il benessere della pelle veicolando efficacemente e quantitativamente sia il paracetamolo che gli agenti farmaceutici o cosmetici in essa presenti. In fact, as it will be seen from the following Examples, this formulation applied topically, has proved to have a good efficacy in promoting the well-being of the skin by effectively and quantitatively conveying both the paracetamol and the pharmaceutical or cosmetic agents present therein.
La composizione e la formulazione oggetto della presente invenzione sono preparate per miscelazione degli ingredienti. The composition and formulation object of the present invention are prepared by mixing the ingredients.
Si riportano di seguito Esempi di realizzazione della presente invenzione forniti a titolo illustrativo. Examples of embodiments of the present invention, provided for illustrative purposes, are reported below.
ESEMPI EXAMPLES
Esempio 1 Example 1
In accordo alla presente invenzione, Ã ̈ stata preparata una composizione avente la seguente composizione A: In accordance with the present invention, a composition has been prepared having the following composition A:
% in peso % by weight
paracetamolo 0,5 paracetamol 0.5
acqua elettrolizzata acida (pH 2,2) 91.6 acid electrolyzed water (pH 2.2) 91.6
poliacrilato di sodio 1,7 sodium polyacrylate 1.7
(1.82% sul veicolo) (1.82% on vehicle)
eccipienti 6,2 excipients 6.2
filler, antiagglomeranti, plasticizzanti, profumo fillers, anti-caking agents, plasticizers, perfume
Esempio 2 Example 2
In accordo alla presente invenzione, Ã ̈ stata preparata una composizione avente la seguente composizione B: In accordance with the present invention, a composition was prepared having the following composition B:
filler, antiagglomeranti, profumo fillers, anti-caking agents, perfume
Esempio 3 Example 3
In accordo alla presente invenzione, Ã ̈ stata preparata una composizione avente la seguente composizione C: According to the present invention, a composition was prepared having the following composition C:
filler, antiagglomeranti, profumo fillers, anti-caking agents, perfume
Esempio 4 Example 4
In accordo alla presente invenzione, Ã ̈ stata preparata una composizione avente la seguente composizione D: In accordance with the present invention, a composition was prepared having the following composition D:
% in peso % by weight
paracetamolo 0,1 paracetamol 0.1
acqua elettrolizzata acida (pH 2,2) 73,3 acid electrolyzed water (pH 2.2) 73.3
poliacrilato di sodio 0,5 sodium polyacrylate 0.5
(0.67% sul veicolo) eccipienti 26,2 (0.67% on vehicle) excipients 26.2
filler, antiagglomeranti, profumo fillers, anti-caking agents, perfume
Esempio 5 Example 5
In accordo alla presente invenzione, Ã ̈ stata preparata una composizione avente la seguente composizione E: In accordance with the present invention, a composition was prepared having the following composition E:
% in peso % by weight
paracetamolo 0,1 paracetamol 0.1
acqua elettrolizzata acida (pH 2,2) 62,5 acid electrolyzed water (pH 2.2) 62.5
poliacrilato di sodio 0,2 sodium polyacrylate 0.2
(0.32% sul veicolo) eccipienti 37,2 (0.32% on vehicle) excipients 37.2
filler, antiagglomeranti, profumo fillers, anti-caking agents, perfume
Esempio 6 Example 6
In accordo alla presente invenzione, Ã ̈ stata preparata una composizione avente la seguente composizione F: In accordance with the present invention, a composition was prepared having the following composition F:
filler, antiagglomeranti, profumo fillers, anti-caking agents, perfume
Esempio 7 Example 7
In accordo alla presente invenzione, Ã ̈ stata preparata una composizione avente la seguente composizione G: According to the present invention, a composition was prepared having the following composition G:
filler, antiagglomeranti, profumo fillers, anti-caking agents, perfume
Esempio 8 Example 8
In accordo alla presente invenzione, à ̈ stata preparata una formulazione impiegando la composizione A dell’Esempio 1 : In accordance with the present invention, a formulation was prepared using composition A of Example 1:
% in peso % by weight
Composizione A 93.8 Composition A 93.8
pantenolo, glicerolo 5,0 panthenol, glycerol 5.0
mannitolo, sodio citrato, 0,5 mannitol, sodium citrate, 0.5
acetil tetrapeptide-15 acetyl tetrapeptide-15
conservanti 0,55 preservatives 0.55
EDTA bisodico 0,15 EDTA disodium 0.15
Questa formulazione trova applicazione come coadiuvante nel trattamento delle scottature e degli eritemi solari. This formulation finds application as an adjuvant in the treatment of sunburn and sunburn.
Esempio 9 Example 9
In accordo alla presente invenzione, à ̈ stata preparata una formulazione impiegando la composizione B dell’Esempio 2: In accordance with the present invention, a formulation has been prepared using the composition B of Example 2:
% in peso % by weight
Composizione B 89,45 Composition B 89.45
pantenolo, glicerolo 5,0 panthenol, glycerol 5.0
mannitolo, sodio citrato, 0,5 mannitol, sodium citrate, 0.5
acetil tetrapeptide-15 acetyl tetrapeptide-15
olio di oliva 1,0 olive oil 1.0
oligosaccaride alfa-glucano 1,5 oligosaccharide alpha-glucan 1,5
salicilato de silanodiol 2,0 salicylate de silanodiol 2.0
conservanti 0,4 preservatives 0.4
EDTA bisodico 0,15 EDTA disodium 0.15
Questa formulazione trova applicazione come coadiuvante nel trattamento della dermatite atopica. This formulation finds application as an adjuvant in the treatment of atopic dermatitis.
Esempio 10 Example 10
In accordo alla presente invenzione, à ̈ stata preparata una formulazione impiegando la composizione C dell’Esempio 3: According to the present invention, a formulation was prepared using the composition C of Example 3:
Questa formulazione trova applicazione come coadiuvante nel trattamento delle rughe, e come anti-age. This formulation finds application as an adjuvant in the treatment of wrinkles, and as an anti-aging.
Esempio 11 Example 11
In accordo alla presente invenzione, à ̈ stata preparata una formulazione impiegando la composizione D dell’Esempio 4: According to the present invention, a formulation was prepared using the composition D of Example 4:
% in peso % by weight
Composizione D 76,7 Composition D 76.7
pantenolo, glicerolo 1,0 panthenol, glycerol 1.0
diglicerina 3,5 diglycerin 3.5
olio di oliva 3,0 olive oil 3.0
estratto di ippocastano 7,0 horse chestnut extract 7.0
estratto di Gingko Biloba 8,0 Gingko Biloba extract 8.0
nicotinato di tocoferile 0,2 0.2 tocopheryl nicotinate
conservanti 0,6 preservatives 0.6
Questa formulazione trova applicazione come coadiuvante nel trattamento della liposclerosi. This formulation finds application as an adjuvant in the treatment of liposclerosis.
Esempio 12 Example 12
In accordo alla presente invenzione, à ̈ stata preparata una formulazione impiegando la composizione E dell’Esempio 5: According to the present invention, a formulation was prepared using the composition E of Example 5:
% in peso % by weight
Composizione E 90,7 Composition E 90.7
pantenolo, glicerolo 1,0 panthenol, glycerol 1.0
diglicerina 3,4 diglycerin 3,4
olio di oliva 0,5 olive oil 0.5
tocoferil acetato 0,5 tocopheryl acetate 0.5
ascorbil palmitato 3,0 ascorbyl palmitate 3.0
conservanti 0,4 preservatives 0.4
acido ialuronico 0,5 0.5 hyaluronic acid
Questa formulazione trova applicazione come coadiuvante nel trattamento delle rughe, e come anti-age. This formulation finds application as an adjuvant in the treatment of wrinkles, and as an anti-aging.
Esempio 13 Example 13
Valutazione della stabilità nel tempo dei cluster di molecole di acqua nell’agente veicolante transepidermico o transdermico dell’invenzione Evaluation of the stability over time of the clusters of water molecules in the transepidermal or transdermal carrier agent of the invention
Tale valutazione à ̈ stata condotta mediante uno studio di Risonanza Magnetica Nucleare effettuata sull’isotopo 17 dell’ossigeno (<17>0-NMR). This evaluation was carried out by means of a Nuclear Magnetic Resonance study carried out on the isotope 17 of oxygen (<17> 0-NMR).
I seguenti campioni sono stati preparati e analizzati: The following samples were prepared and analyzed:
- campione A = acqua distillata - sample A = distilled water
- campione B = acqua elettrolizzata acida (pH 2,2) sodio poliacrilato (0,001% in peso sul peso del campione B) - sample B = acid electrolyzed water (pH 2.2) sodium polyacrylate (0.001% by weight on the weight of sample B)
- campione C = campione B a distanza di 1 mese dalla preparazione - sample C = sample B 1 month after preparation
Le analisi mediante<17>0-NMR permettono di valutare lo stato di aggregazione delle molecole di H20, fornendo un segnale o picco la cui larghezza (misurata a metà altezza) indicata con ΔV1⁄2e la frequenza di risonanza Î ́ (misurata in Hertz o parti per milione, rispettivamente Hz o Î ́ /ppm) sono parametri strettamente correlati al numero di molecole che compongono il cluster: in particolare tanto più é piccola l’ampiezza del segnale NMR, tanto più basso e il numero di molecole di H20 che compongono il cluster. The analyzes using <17> 0-NMR allow to evaluate the state of aggregation of the H20 molecules, providing a signal or peak whose width (measured at half height) indicated with Î "V1⁄2 and the resonance frequency Î ́ (measured in Hertz or parts per million, respectively Hz or Î ́ / ppm) are parameters strictly related to the number of molecules that make up the cluster: in particular, the smaller the amplitude of the NMR signal, the lower the number of molecules of H20 that make up the cluster.
Infatti, la spettroscopia NMR à ̈ estremamente sensibile all’intorno dei nuclei ed alle loro interazioni, per cui anche piccole variazioni della geometria del cluster e/o cambiamenti di forze d’associazione tra le molecole possono generare significative variazioni nei tempi di rilassamento dell'acqua e di conseguenza nell’aspetto dei segnali NMR. In fact, NMR spectroscopy is extremely sensitive to the surroundings of nuclei and their interactions, so even small variations in the geometry of the cluster and / or changes in the forces of association between molecules can generate significant variations in the relaxation times. water and consequently in the aspect of NMR signals.
Parametri di acquisizione degli spettri<17>Q-NMR: Acquisition parameters of the <17> Q-NMR spectra:
Ampiezza spettrale SW = 200 ppm Spectral width SW = 200 ppm
Tempo d'acquisizione AQ =1.0 sec. AQ acquisition time = 1.0 sec.
Numero di scansioni NS = 350 Number of NS scans = 350
Tempo d’attesa D1 = 0.5 sec Waiting time D1 = 0.5 sec
Line broadening (prima della trasformata di Fourier) 1 Hz Line broadening (before Fourier transform) 1 Hz
Nella Figura 1 sono riportati in successione gli spettri dei tra campioni di cui sopra. Figure 1 shows the spectra of the above samples in succession.
La frequenza di risonanza à ̈ per tutti e tre i campioni : Î ́ = 2.671. The resonant frequency is for all three samples: Î ́ = 2.671.
Gli spettri sono riferiti al picco di risonanza<17>0 dell’acqua deuterata esterna (D2O): Î ́ = 0 The spectra refer to the resonance peak <17> 0 of the external deuterated water (D2O): Î ́ = 0
Risultati Results
Si notava che le differenze tre le rispettive ampiezze di linea (ΔÎ1⁄2-ι/2: ampiezza del segnale a mezza altezza) erano significativamente diverse: It was noted that the differences between the respective line amplitudes (Î ”Î1⁄2-ι / 2: signal amplitude at half height) were significantly different:
Campione A: ΔÎ1⁄21⁄2 = 112 Hz Sample A: Î ”Î1⁄21⁄2 = 112 Hz
Campione B : ΔÎ1⁄21⁄2 = 58 Hz Sample B: Î ”Î1⁄21⁄2 = 58 Hz
Campione C: 1⁄2 = Hz Sample C: 1⁄2 = Hz
Tali differenze erano rappresentative del fatto che l’acqua distillata (campione A) comprende cluster di 10-15 molecole di H20, mentre l’acqua elettrolizzata acida impiegata nell’agente veicolante dell’invenzione comprende cluster di soltanto 5-6 molecole di H20. Tale risultato si manteneva invariato anche dopo un mese dalla preparazione del campione B, come mostra lo spettro del campione C. These differences were representative of the fact that distilled water (sample A) comprises clusters of 10-15 molecules of H20, while the acid electrolyzed water used in the carrier of the invention comprises clusters of only 5-6 molecules of H20. This result remained unchanged even after one month from the preparation of sample B, as shown by the spectrum of sample C.
Tale risultato à ̈ considerevolmente vantaggioso in quanto acqua elettrolizzata acida comprendente cluster di queste dimensioni viene assorbita dalla pelle in maniera estremamente più efficace dell’acqua distillata. Inoltre, nella forma di agente veicolante transepidermico 0 transdermico secondo la presente invenzione, detta acqua elettrolizzata acida à ̈ anche convenientemente molto stabile. This result is considerably advantageous as acidic electrolyzed water comprising clusters of this size is absorbed by the skin in an extremely more effective way than distilled water. Furthermore, in the form of transepidermal or transdermal carrier agent according to the present invention, said acid electrolyzed water is also conveniently very stable.
Esempio 14 Example 14
Valutazione della capacità delle composizione dell’invenzione di veicolare il paracetamolo Evaluation of the ability of the composition of the invention to convey paracetamol
Sulla composizione dell’Esempio 1 à ̈ stata effettuata una valutazione in vitro dell'assorbimento percutaneo di paracetamolo su epidermide ricostituita in grado di simulare le condizioni in vivo. Tale epidermide ricostruita rappresenta un modello cellulare tridimensionale ed à ̈ costituita da cheratinociti primari umani normali, lasciati crescere in vitro in modo da simulare l'architettura pluristratificata dell'epidermide umana, con uno strato corneo ben differenziato. Il modello à ̈ stato acquistato da CellSystems® (Troisdorf, Germania Lotto EST-120625-001). An in vitro evaluation of the percutaneous absorption of paracetamol on reconstituted epidermis able to simulate the conditions in vivo was carried out on the composition of Example 1. This reconstructed epidermis represents a three-dimensional cellular model and is made up of normal human primary keratinocytes, left to grow in vitro in order to simulate the multilayered architecture of the human epidermis, with a well-differentiated stratum corneum. The model was purchased from CellSystems® (Troisdorf, Germany Lot EST-120625-001).
Da una sezione trasversale di tale modello coltivato in vitro, si vedevano i diversi strati dell’epidermide e uno strato corneo ben differenziato in superficie di colore rosa. Il prodotto da testare era applicato sullo strato corneo, mentre al di sotto deH’epidermide si trovava una membrana semipermeabile che comunicava con il pozzetto inferiore dove si trovava il medium di coltura. From a cross-section of this model cultivated in vitro, the different layers of the epidermis and a well-differentiated stratum corneum on the surface of pink color were seen. The product to be tested was applied to the stratum corneum, while below the epidermis there was a semipermeable membrane that communicated with the lower well where the culture medium was.
Le unità di epidermide artificiale (0,5cm<2>) sono state trattate con il campione dell’Esempio 1 dosandolo accuratamente tramite pipetta speciale per liquidi densi P100 Gilson a spostamento positivo e applicando 30Î1⁄4Ι di ciascun campione contenente paracetamolo, ovvero circa 150 Î1⁄4g di principio attivo. The units of artificial epidermis (0.5cm <2>) were treated with the sample of Example 1 by dosing it accurately using a special pipette for dense liquids P100 Gilson with positive displacement and applying 30Î1⁄4Î ™ of each sample containing paracetamol, that is about 150 Î1⁄4g of active ingredient.
I campioni ed i controlli sono stati incubati a 37°C, 5% C02e l’esposizione à ̈ stata effettuata per 30’, 2 e 6 ore. Il campione à ̈ stato testato in triplicato. The samples and controls were incubated at 37 ° C, 5% C02 and exposure was carried out for 30, 2 and 6 hours. The sample was tested in triplicate.
Ai diversi tempi di esposizione sono stati effettuati dei prelievi del sottonatante con una pipetta. I campioni così recuperati sono stati immediatamente congelati a -20°C e scongelati successivamente per le analisi cromatografiche quantitative. II quantitativo permeato sotto l’epidermide di paracetamolo à ̈ stato diluito in parti uguali con metanolo. La soluzione così ottenuta à ̈ stata quantizzata tramite HPLC e rilevatore DAD. Il metodo di analisi à ̈ stato sviluppato in accordo a quanto riportato dalla farmacopea europea per il composto Paracetamolo Method 01/2008:0049 corrected 6.0. At different exposure times, samples of the undernatant were taken with a pipette. The samples thus recovered were immediately frozen at -20 ° C and subsequently thawed for quantitative chromatographic analyzes. The quantity of paracetamol permeated under the epidermis was diluted in equal parts with methanol. The resulting solution was quantized by HPLC and DAD detector. The analysis method was developed in accordance with the European pharmacopoeia for the compound Paracetamol Method 01/2008: 0049 corrected 6.0.
Al terreno di crescita, con il quantitativo incognito di paracetamolo proveniente dall’assorbimento percutaneo, à ̈ stato aggiunto un uguale quantitativo di metanolo (1 :1 ). La soluzione così ottenuta à ̈ stata preparata per l'iniezione in HPLC. An equal amount of methanol (1: 1) was added to the growth medium, with the unknown quantity of paracetamol coming from percutaneous absorption. The resulting solution was prepared for injection into HPLC.
I valori espressi nella sottostante Tabella 1 si riferiscono quindi alle quantità totali di paracetamolo permeate nel sottonatante e le rispettive percentuali rispetto alla quantità totale iniziale ponendo la densità =1,0 e titolo dell’attivo 0,5%. The values expressed in Table 1 below therefore refer to the total quantities of paracetamol permeated into the underlying and the respective percentages with respect to the initial total quantity, setting the density = 1.0 and the title of the active 0.5%.
Tabella 1. Media % di paracetamolo presente nel sottonatante Table 1. Average% of paracetamol present in the underlying
L’analisi in HPLC-DAD rilevava quindi a 6 ore il rilascio massimo, nel sottonatante, di paracetamolo, pari a 16,7%. Si rilevava inoltre che, sorprendentemente, già dopo soli 30 minuti, il paracetamolo era riscontrabile nel sottonatante, ad indicare l’immediatezza dell’assorbimento percutaneo grazie alla composizione della presente invenzione. The HPLC-DAD analysis therefore revealed the maximum release of 16.7% of paracetamol in the subnatant at 6 hours. It was also noted that, surprisingly, already after only 30 minutes, paracetamol was found in the subnatant, indicating the immediacy of percutaneous absorption thanks to the composition of the present invention.
È stato, inoltre, effettuato un test MTT per valutare la citotossicità della composizione dell’invenzione dopo 6 h dall’inizio dell’applicazione sull’epidermide ricostruita. L’esito di tale test à ̈ riportato nella Tabella 2 seguente. In addition, an MTT test was carried out to evaluate the cytotoxicity of the composition of the invention after 6 hours from the beginning of the application on the reconstructed epidermis. The result of this test is shown in Table 2 below.
Tabella 2. % vitalità cellulare Table 2.% cell viability
Dopo 6 h After 6 h
% Media % Average
97,2 97.2
Campione Sample
97,3 96,8 97.3 96.8
Esempio 1 Example 1
96,0 96.0
I campioni dell’Esempio 1 presentavano dunque una adeguata biocompatibilità nei confronti dell’epidermide dopo 6 ore di trattamento. The samples of Example 1 therefore showed an adequate biocompatibility towards the epidermis after 6 hours of treatment.
Dalla descrizione dettagliata e dagli Esempi sopra riportati, risultano evidenti i vantaggi conseguiti mediante la composizione della presente invenzione. In particolare, tale composizione si à ̈ mostrata sorprendentemente e vantaggiosamente in grado di somministrare una quantità immediatamente biodisponibile di paracetamolo, tale da consentire al paracetamolo di espletare la sua funzione rapidamente ed efficacemente. Inoltre, il fatto che questa molecola sia somministrabile transepidermicamente o transdermicamente grazie alla opportuna scelta dell’agente veicolante risulta ancora più sorprendente. From the detailed description and the Examples reported above, the advantages achieved by the composition of the present invention are evident. In particular, this composition has shown surprisingly and advantageously to be able to administer an immediately bioavailable quantity of paracetamol, such as to allow the paracetamol to perform its function quickly and effectively. Furthermore, the fact that this molecule can be administered transepidermally or transdermally thanks to the appropriate choice of the carrier agent is even more surprising.
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT001965A ITMI20121965A1 (en) | 2012-11-19 | 2012-11-19 | TOPIC COMPOSITION FOR TRANSEPIDERMIC OR TRANSDERMIC RELEASE OF PARACETAMOL |
PCT/IB2013/060104 WO2014076642A1 (en) | 2012-11-19 | 2013-11-13 | Topical composition for the transepidermal or transdermal delivery of paracetamol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT001965A ITMI20121965A1 (en) | 2012-11-19 | 2012-11-19 | TOPIC COMPOSITION FOR TRANSEPIDERMIC OR TRANSDERMIC RELEASE OF PARACETAMOL |
Publications (1)
Publication Number | Publication Date |
---|---|
ITMI20121965A1 true ITMI20121965A1 (en) | 2014-05-20 |
Family
ID=47631652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT001965A ITMI20121965A1 (en) | 2012-11-19 | 2012-11-19 | TOPIC COMPOSITION FOR TRANSEPIDERMIC OR TRANSDERMIC RELEASE OF PARACETAMOL |
Country Status (2)
Country | Link |
---|---|
IT (1) | ITMI20121965A1 (en) |
WO (1) | WO2014076642A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106176274B (en) * | 2016-08-26 | 2020-04-10 | 深圳市维琪医药研发有限公司 | Polypeptide composition with anti-allergy effect |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007048772A1 (en) * | 2005-10-28 | 2007-05-03 | Akuatech S.R.L. | New highly stable aqueous solution, electrode with nanocoating for preparing the solution and method for making this electrode |
EP2082751A2 (en) * | 2008-01-25 | 2009-07-29 | Gian Battista Ceresa | Topical formulations in the form of aqueous gels fro the treatment of disorders of the skin and mucous membranes or as vehicules for transdermal administration of natural extractive preparations, substances, molecules and drugs |
-
2012
- 2012-11-19 IT IT001965A patent/ITMI20121965A1/en unknown
-
2013
- 2013-11-13 WO PCT/IB2013/060104 patent/WO2014076642A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007048772A1 (en) * | 2005-10-28 | 2007-05-03 | Akuatech S.R.L. | New highly stable aqueous solution, electrode with nanocoating for preparing the solution and method for making this electrode |
EP2082751A2 (en) * | 2008-01-25 | 2009-07-29 | Gian Battista Ceresa | Topical formulations in the form of aqueous gels fro the treatment of disorders of the skin and mucous membranes or as vehicules for transdermal administration of natural extractive preparations, substances, molecules and drugs |
Also Published As
Publication number | Publication date |
---|---|
WO2014076642A1 (en) | 2014-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yokota et al. | Influence of nanoparticle size on the skin penetration, skin retention and anti-inflammatory activity of non-steroidal anti-inflammatory drugs | |
Todosijević et al. | Biocompatible microemulsions of a model NSAID for skin delivery: A decisive role of surfactants in skin penetration/irritation profiles and pharmacokinetic performance | |
KR20050047525A (en) | Carrier | |
KR20080092373A (en) | Therapeutic compositions | |
Baek et al. | Enhanced transdermal drug delivery of zaltoprofen using a novel formulation | |
Saino et al. | Optimization of skin permeation and distribution of ibuprofen by using nanostructures (coagels) based on alkyl vitamin C derivatives | |
JP2010522730A (en) | Ibuprofen, complex of cyclodextrin and third agent, and method of use in pharmacy | |
Salah et al. | Starch nanoparticles improve curcumin-induced production of anti-inflammatory cytokines in intestinal epithelial cells | |
JP5732471B2 (en) | Pharmaceutical composition or analogue comprising a solvent mixture and a vitamin D derivative | |
ES2689070T3 (en) | Topical pharmaceutical composition, method for producing the topical pharmaceutical composition, use of the topical pharmaceutical composition and method for the topical treatment of psoriasis, atopic dermatitis or chronic eczema | |
Hao et al. | Effect and mechanism of penetration enhancement of organic base and alcohol on Glycyrrhetinic acid in vitro | |
ITMI20111806A1 (en) | COMPOSITION FOR THE TREATMENT OF SKIN LESIONS | |
JP4931369B2 (en) | Liposomes and therapeutic compositions containing the same | |
ITBO20060313A1 (en) | PHARMACEUTICAL FORMULATIONS FOR TRANSDERMAL USE | |
JP4791082B2 (en) | Liposomes and topical skin preparations containing the same | |
EP2813215B1 (en) | 2,2',6,6'-tetraisopropyl-4,4'-2-biphenol lipid microsphere preparation and preparation method therefor | |
EP2854801B1 (en) | Topical aqueous gel composition in the form of an homogenous suspension of a retinoid containing at least one hydrophobic silica | |
ITMI20121965A1 (en) | TOPIC COMPOSITION FOR TRANSEPIDERMIC OR TRANSDERMIC RELEASE OF PARACETAMOL | |
CA2231118C (en) | Pharmaceutical preparation containing nimesulide for topical use | |
JP2021508334A (en) | Topical preparations for the treatment of skin disorders including male baldness | |
CN113543773B (en) | Stable topical fenoldopam compositions | |
BR112018017147B1 (en) | Topical composition based on a carmosine-magnesium complex and production method of the carmosine-magnesium complex | |
Kan et al. | Evaluation of pharmacokinetics and pharmacodynamics relationships for Salvianolic Acid B micro-porous osmotic pump pellets in angina pectoris rabbit | |
JP6656890B2 (en) | Filaggrin production promoter | |
JPWO2008111296A1 (en) | Pharmaceuticals for the prevention and treatment of skin diseases caused by increased keratinization |